Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C35H58N5O6P |
| Molecular Weight | 675.8387 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OCC3=CC=CC=C3
InChI
InChIKey=AHSNBFKBLUUKAW-UHFFFAOYSA-N
InChI=1S/C35H58N5O6P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-20-24-43-26-27-45-47(42,46-28-31-21-18-17-19-22-31)30-44-25-23-40-29-37-32-33(40)38-35(36)39-34(32)41/h17-19,21-22,29H,2-16,20,23-28,30H2,1H3,(H3,36,38,39,41)
| Molecular Formula | C35H58N5O6P |
| Molecular Weight | 675.8387 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Rabacfosadine was approved in 2017 under the brand name Tanovea-CA1 for the treatment of canine lymphoma. In addition, this drug has demonstrated effectiveness against non-Hodgkin's lymphoma in dogs, as well as canine cutaneous T-cell lymphoma, and relapsed canine B-cell lymphoma. Rabacfosadine a prodrug, which is hydrolyzed intracellularly to the metabolites, 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine (cPrPMEDAP) and 9-(2-phosphonylmethoxyethyl) guanine (PMEG). PMEG is then converted to its active phosphorylated form, which is a chain-terminating inhibitor of the replicative deoxyribonucleic acid (DNA) polymerases.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=407d42d7-2e23-4e90-aff0-b8b05d226e4b
Curator's Comment: in dogs
Administer TANOVEA-CA1 at 1 mg/kg body weight as a 30-minute intravenous infusion, once every three weeks, for up to five doses. Stepwise dose reductions to 0.8 mg/kg and 0.66 mg/kg or dose delays may be used to manage adverse reactions.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 21:32:58 GMT 2025
by
admin
on
Tue Apr 01 21:32:58 GMT 2025
|
| Record UNII |
A1DXM66YHY
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
A1DXM66YHY
Created by
admin on Tue Apr 01 21:32:58 GMT 2025 , Edited by admin on Tue Apr 01 21:32:58 GMT 2025
|
PRIMARY | |||
|
135565845
Created by
admin on Tue Apr 01 21:32:58 GMT 2025 , Edited by admin on Tue Apr 01 21:32:58 GMT 2025
|
PRIMARY | |||
|
1626364-18-8
Created by
admin on Tue Apr 01 21:32:58 GMT 2025 , Edited by admin on Tue Apr 01 21:32:58 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |